Clinical Trial Update: Decitabine Versus Azacitidine in Myelodysplastic Syndrome Patients With Low and Intermediate-1 Risk [Phase 2]

View source ↗

Summary

Phase 2 trial comparing decitabine to azacitidine in myelodysplastic syndrome patients with low and intermediate-1 risk; results completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndrome

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Decitabine (Decitabine)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2020-12-24